Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Completed · Phase 1 · Has a placebo group

Conditions studied: HIV-1 Infection

In brief

The primary objectives of this study are to evaluate the safety and tolerability of escalating, multiple doses of vesatolimod (formerly GS-9620) in HIV-1 infected virologically suppressed adults on antiretroviral therapy (ART) and to evaluate the virologic effect of vesatolimod as measured by changes in plasma HIV-1 RNA.

Key facts

Study ID

NCT02858401

Run by

Gilead Sciences

People needed

48

Starts

2015-01-29

Expected to finish

2019-02-14

Last updated by the study team

2020-02-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mills Clinical Research — Los Angeles, California, United States
• UCSD Antiviral Research Center (AVRC) — San Diego, California, United States
• Midway Immunology & Research Center — Ft. Pierce, Florida, United States
• Orlando Immunology Center Recruiting — Orlando, Florida, United States
• Ohio State University Infectious Diseases Research — Columbus, Ohio, United States
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Central Texas Clinical Research — Austin, Texas, United States
• Peter Shalit, MD — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.